塔尔苏斯制药

最新新闻

• 评级变动
  William Blair Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• Jefferies Initiates Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Announces Target Price $105
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Cuts Target Price to $89
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 评级变动
  Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $97
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 评级变动
  LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $104
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $98
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• 评级变动
  Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Cuts Target Price to $98
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• A Quick Look at Today's Ratings for Tarsus Pharmaceuticals(TARS.US), With a Forecast Between $90 to $100
  \u5e02\u573a\u8d44\u8baf · 2026/7/14
• 评级变动
  Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $100
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  A Quick Look at Today's Ratings for Tarsus Pharmaceuticals(TARS.US), With a Forecast Between $88 to $100
  \u5e02\u573a\u8d44\u8baf · 2026/7/9
• Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $110
  \u5e02\u573a\u8d44\u8baf · 2026/9/17
• 评级变动
  Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100
  \u5e02\u573a\u8d44\u8baf · 2026/7/10
• 评级变动
  Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $100
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $104
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  H.C. Wainwright Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $88
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Prime Medicine, Inc. (PRME) and Ascendis Pharma (ASND)
  TipRanks · 2026/7/9
• 评级变动
  Oppenheimer Initiates Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Announces Target Price $97
  \u5e02\u573a\u8d44\u8baf · 2026/7/14
• Goldman Sachs Upgrades Tarsus Pharmaceuticals(TARS.US) to Buy Rating, Raises Target Price to $116
  \u5e02\u573a\u8d44\u8baf · 2026/9/24

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。